These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32403054)

  • 21. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
    Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4.
    Li Y; Chen R; Bowden M; Mo F; Lin YY; Gleave M; Collins C; Dong X
    Oncotarget; 2017 Sep; 8(40):66878-66888. PubMed ID: 28978002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
    Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
    Lee AR; Che N; Lovnicki JM; Dong X
    Front Oncol; 2018; 8():93. PubMed ID: 29666783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
    Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
    Kashyap V; Ahmad S; Nilsson EM; Helczynski L; Kenna S; Persson JL; Gudas LJ; Mongan NP
    Mol Oncol; 2013 Jun; 7(3):555-66. PubMed ID: 23384557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
    Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
    Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
    Sehrawat A; Gao L; Wang Y; Bankhead A; McWeeney SK; King CJ; Schwartzman J; Urrutia J; Bisson WH; Coleman DJ; Joshi SK; Kim DH; Sampson DA; Weinmann S; Kallakury BVS; Berry DL; Haque R; Van Den Eeden SK; Sharma S; Bearss J; Beer TM; Thomas GV; Heiser LM; Alumkal JJ
    Proc Natl Acad Sci U S A; 2018 May; 115(18):E4179-E4188. PubMed ID: 29581250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Silencing of SRRM4 suppresses microexon inclusion and promotes tumor growth across cancers.
    Head SA; Hernandez-Alias X; Yang JS; Ciampi L; Beltran-Sastre V; Torres-Méndez A; Irimia M; Schaefer MH; Serrano L
    PLoS Biol; 2021 Feb; 19(2):e3001138. PubMed ID: 33621242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.
    Qian C; Yang Q; Rotinen M; Huang R; Kim H; Gallent B; Yan Y; Cadaneanu RM; Zhang B; Kaochar S; Freedland SJ; Posadas EM; Ellis L; Di Vizio D; Morrissey C; Nelson PS; Brady L; Murali R; Campbell MJ; Yang W; Knudsen BS; Mostaghel EA; Ye H; Garraway IP; You S; Freeman MR
    Nucleic Acids Res; 2024 Jul; 52(13):7740-7760. PubMed ID: 38932701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
    Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM
    Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The β
    Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
    Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
    Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
    Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.
    Crea F; Venalainen E; Ci X; Cheng H; Pikor L; Parolia A; Xue H; Nur Saidy NR; Lin D; Lam W; Collins C; Wang Y
    Epigenomics; 2016 May; 8(5):721-31. PubMed ID: 27096814
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
    Bae SY; Bergom HE; Day A; Greene JT; Sychev ZE; Larson G; Corey E; Plymate SR; Freedman TS; Hwang JH; Drake JM
    Front Endocrinol (Lausanne); 2023; 14():1093332. PubMed ID: 37065756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
    Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
    Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
    Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
    Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.
    Sulsenti R; Scialpi GB; Frossi B; Botti L; Ferri R; Tripodi I; Piva A; Sangaletti S; Pernici D; Cancila V; Romeo F; Chiodoni C; Lecis D; Bianchi F; Fischetti I; Enriquez C; Crivelli F; Bregni M; Renne G; Pece S; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Cancer Immunol Res; 2024 Sep; 12(9):1147-1169. PubMed ID: 38869181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.